Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, open, and positive parallel controlled, Phase III clinical trial to evaluate the efficacy and safety of recombinant Insulin Aspart injection (HS005) and NovoRapid in the treatment of diabetes

Next Previous
Trial Profile

Multicenter, randomized, open, and positive parallel controlled, Phase III clinical trial to evaluate the efficacy and safety of recombinant Insulin Aspart injection (HS005) and NovoRapid in the treatment of diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin glargine; Metformin
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 03 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top